You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Mallinckrodt
McKesson
Dow
Boehringer Ingelheim

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Patent: 5,739,407

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,739,407
Title: Human .beta.-casein, process for producing it and use thereof
Abstract:The present invention relates to a DNA sequence encoding the human milk protein .beta.-casein or an analogue or variant thereof which has either the calcium binding activity of human .beta.-casein, or opioid activity, or angiotensin converting enzyme (ACE) inhibitory activity, or a combination of any two or three of these activities. The DNA sequence may optionally contain one or more intron sequences and permissive RNA splice signals. The DNA sequence is used in the production of recombinant human .beta.-casein, advantageously by means of production in transgenic non-human mammals such as bovine species. In one embodiment, the DNA sequence is inserted into a milk protein gene of a mammal such as a whey acidic protein (WAP) gene. The main use of the recombinant human .beta.-casein is as a constituent of infant formulae. It is contemplated that the recombinant human .beta.-casein provides a substantial improvement of the nutritional and biological value of the formulae in that a closer similarity to human milk is obtained.
Inventor(s): Bergstrom; Sven (Umea, SE), Hernell; Olle (Umea, SE), Lonnerdal; Bo (Davis, CA), Hjalmarsson; Karin (Umea, SE), Hanson; Lennart (Umea, SE), Tornell; Jan (Goteborg, SE), Stromqvigt; Mats (Umea, SE)
Assignee: Symbicom aktiebolag (Umea, SE)
Application Number:08/078,090
Patent Claims:see list of patent claims

Details for Patent 5,739,407

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Symbicom aktiebolag (Umea, SE) 2015-04-14 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Symbicom aktiebolag (Umea, SE) 2015-04-14 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Symbicom aktiebolag (Umea, SE) 2015-04-14 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Moodys
McKesson
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.